Eagle Pharmaceuticals Analyst Ratings
Eagle Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | -15.15% | Piper Sandler | $26 → $17 | Downgrades | Neutral → Underweight |
| 03/02/2020 | 129.6% | Cantor Fitzgerald | $58 → $46 | Maintains | Neutral |
| 03/22/2019 | 104.64% | Mizuho | $40 → $41 | Maintains | Neutral |
| 10/31/2018 | 169.53% | Piper Sandler | $82 → $54 | Downgrades | Overweight → Neutral |
| 09/21/2018 | 299.3% | Cantor Fitzgerald | $81 → $80 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/09/2023 | -15.15% | 派珀·桑德勒 | 26 美元 → 17 美元 | 降級 | 中性 → 體重不足 |
| 03/02/2020 | 129.6% | 坎託·菲茨傑拉德 | 58 美元 → 46 美元 | 維持 | 中立 |
| 03/22/2019 | 104.64% | 瑞穗市 | 40 美元 → 41 美元 | 維持 | 中立 |
| 10/31/2018 | 169.53% | 派珀·桑德勒 | 82 美元 → 54 美元 | 降級 | 超重 → 中性 |
| 09/21/2018 | 299.3% | 坎託·菲茨傑拉德 | 81 美元 → 80 美元 | 維持 | 超重 |
What is the target price for Eagle Pharmaceuticals (EGRX)?
鷹製藥（EGRX）的目標價格是多少？
The latest price target for Eagle Pharmaceuticals (NASDAQ: EGRX) was reported by Piper Sandler on August 9, 2023. The analyst firm set a price target for $17.00 expecting EGRX to fall to within 12 months (a possible -15.15% downside). 1 analyst firms have reported ratings in the last year.
派珀·桑德勒於2023年8月9日公佈了鷹製藥（納斯達克股票代碼：EGRX）的最新目標股價。該分析公司將目標股價設定爲17.00美元，預計EGRX將在12個月內跌至-15.15％（下跌幅度可能爲-15.15％）。去年有1家分析公司公佈了評級。
What is the most recent analyst rating for Eagle Pharmaceuticals (EGRX)?
鷹製藥（EGRX）的最新分析師評級是多少？
The latest analyst rating for Eagle Pharmaceuticals (NASDAQ: EGRX) was provided by Piper Sandler, and Eagle Pharmaceuticals downgraded their underweight rating.
鷹製藥（納斯達克股票代碼：EGRX）的最新分析師評級由派珀·桑德勒提供，鷹製藥下調了減持評級。
When is the next analyst rating going to be posted or updated for Eagle Pharmaceuticals (EGRX)?
Eagle Pharmicals（EGRX）的下一個分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eagle Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eagle Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Eagle Pharmicals的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Eagle Pharmicals的最新評級是在2023年8月9日提交的，因此您應該預計下一個評級將在2024年8月9日左右公佈。
Is the Analyst Rating Eagle Pharmaceuticals (EGRX) correct?
分析師評級鷹製藥（EGRX）是否正確？
While ratings are subjective and will change, the latest Eagle Pharmaceuticals (EGRX) rating was a downgraded with a price target of $26.00 to $17.00. The current price Eagle Pharmaceuticals (EGRX) is trading at is $20.04, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但鷹製藥（EGRX）的最新評級被下調，目標股價爲26.00美元至17.00美元。鷹製藥（EGRX）目前的交易價格爲20.04美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。